Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cancer

Warfarin use associated with lower incidence of cancer in people aged 50 or older

A Norwegian cohort study finds that warfarin has broad anticancer potential, which could have implications for medication choice for patients needing anticoagulation

Warfarin tablet

Source: TEK Image / Science Photo Library

Study showed warfarin users had a significantly lower incidence of cancer in all sites as well as in prevalent organ-specific sites, such as lung, prostate and breast

Warfarin is the most used anticoagulant worldwide and its anti-tumour potential has been demonstrated in different experimental cancer model systems.

In a Norwegian cohort study published in JAMA Internal Medicine (online, 6 November 2017), 1,256,725 individuals born between 1924 and 1954 were divided into two groups: warfarin users (92,942) and non-users (1,163,783)[1]. Warfarin users comprised individuals taking at least six months of a prescription with at least two years from first prescription to any cancer diagnosis.

After adjusting for age and sex, it was found that, compared with non-users, warfarin users had a significantly lower incidence of cancer in all sites (incidence rate ratio [IRR], 0.84; 95% confidence interval [CI], 0.82-0.86) as well as in prevalent organ-specific sites, such as lung (IRR, 0.80 [95% CI, 0.75-0.86); prostate (IRR, 0.69, 95% CI, 0.65-0.72] and breast (IRR 0.90; 95% CI, 0.82-1.00).

Warfarin use may have broad anticancer potential in individuals aged 50 years or older. This finding could have important implications for the selection of medications for patients needing anticoagulation, the authors concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204216

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Warfarin tablet

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.